by RNA Diagnostics | Sep 10, 2021 | Uncategorized
TORONTO, CANADA — (September 9, 2021) Rna Diagnostics Inc., a leading precision cancer diagnostics company, announced the closing of a CDN $8.0 M series A financing led by iGan Partners and BDC Capital, through its Bridge Financing Program. “The continued...
by RNA Diagnostics | Nov 8, 2018 | Uncategorized
Rna Diagnostics Inc., a Canadian company with a patented platform technology providing real-time cancer therapy guidance, announced today the closing of a $5 million Series A financing. The funding was led by iGAN Partners and includes new and existing investors. Rna...
by RNA Diagnostics | May 24, 2018 | Uncategorized
NEW YORK (GenomeWeb) Rna Diagnostics, a Canadian molecular diagnostics company, recently commenced a clinical trial to validate an assay it plans to commercialize that can be used to guide breast cancer treatment. The trial, called Breast Cancer Response Evaluation...
by RNA Diagnostics | Apr 27, 2018 | Uncategorized
Rna Diagnostics Inc., a Canadian company with a patented platform technology providing real-time cancer therapy guidance, announced enrollment of the first patient in the BREVITY trial at the Azienda Socio-Sanitaria Territoriale di Cremona in Cremona, Italy today....
by RNA Diagnostics | Jul 6, 2017 | Uncategorized
Rna Diagnostics Inc. announced today that Dr. Matthew P. Goetz, Consultant and Professor at Mayo Clinic, Rochester, MN has been appointed to the company’s Clinical Advisory Board (CAB). “Dr. Goetz brings a wealth of scientific knowledge and clinical trial experience...
by RNA Diagnostics | Jun 14, 2017 | Uncategorized
Rna Diagnostics announced the launch of an international prospective clinical trial to validate the RNA Disruption Assay™ (RDA™) as a tool for treatment management of primary breast cancer. BREVITY (Breast Cancer Response EValuation for Individualized TherapY) will...
by RNA Diagnostics | Sep 15, 2016 | Uncategorized
A new study provides further evidence that the Rna Disruption Assay™ (RDA™) may be a useful tool to predict the clinical outcome of neoadjuvant chemotherapy in breast cancer patients. RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant...
by RNA Diagnostics | Apr 1, 2016 | Uncategorized
Rna Diagnostics Inc. appoints Dr. Jeremy Bridge-Cook President and CEO Dr. Ken Pritzker, on behalf of the Board of Directors of Rna Diagnostics Inc., is pleased to announce the appointment of Dr. Jeremy Bridge-Cook to the position of President and Chief Executive...
by RNA Diagnostics | Mar 10, 2016 | Uncategorized
Rna Diagnostics announces the publication of a study on February 24 2016 in the journal BMC Cancer entitled RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines. The study concludes that RNA disruption, as assessed...
by RNA Diagnostics | Feb 18, 2016 | Uncategorized
Rna Diagnostics Inc. announced today that Paul Lucas, an accomplished veteran of the Life Sciences industry, has joined the Company’s Board of Directors. “Paul brings a wealth of proven business and Life Science innovation insight to Rna Diagnostics,” said Dr. Ken...
